CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1029 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-20

Study Completion Date

2023-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete revascularization and perform whole-exome sequencing for enrolled patients to identify the prevalence of CHIP mutations. After 1-year follow-up, the relationship of presence of CHIP mutations and the occurrence of MACCEs will be explored, irrespective of smoking cessation or not. CHIP may be a potential risk factor of poor prognosis of ACS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CHIP/CCUS Natural History Protocol

NCT04102423

Clonal Hematopoiesis of Indeterminate Potential Clonal Cytopenia of Undetermined Significance

RECRUITING

SMS - Study of Somatic Mutations Using Genome Sequencing

NCT06851052

Somatic Mutation

ENROLLING_BY_INVITATION

Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm

NCT01801488

Arteriovenous Malformations Intracranial Aneurysm Subarachnoid Hemorrhage

TERMINATED

Study on the Association Between SXCI and RM and the Possible Genetic Mechanism

NCT02504281

Infertility Female Recurrent Miscarriage

COMPLETED

Genetic Variation in Platelet Aggregation

NCT01576536

Myocardial Infarction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ACS Clonal Hematopoiesis of Indeterminate Potential Smoking Cessation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Current-smoking

exposure: smoking

clonal hematopoiesis of indeterminate potential

Intervention Type GENETIC

Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)

Smoking-cessation

exposure: smoking cessation

clonal hematopoiesis of indeterminate potential

Intervention Type GENETIC

Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)

non-smoking

exposure: none

clonal hematopoiesis of indeterminate potential

Intervention Type GENETIC

Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clonal hematopoiesis of indeterminate potential

Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. In-patients with acute coronary syndrome to undergo PCI 2. Complete revascularization during the index hospitalization 3. Written informed consent

Exclusion Criteria

* 1\. Periprocedural complications (coronary artery dissection, perforation, myocardial infarction, stroke, death) 2. Planned coronary revascularization at discharge 3. Patients with severe chronic disease (uremia, liver cirrhosis, COPD (chronic obstructive pulmonary disease) 4. Abnormal blood counts caused by hematological diseases 5. Diagnosed malignancy

Eligible Sex

ALL

Accepts Healthy Volunteers

No